16 completed. 16 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 16 |
| Phase 2 | 4 | Completed 4 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients Nilotinib (Tasigna ®), capsules of 150 mg, Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) - Chronic Myeloid Leukemia | Phase 3 | Completed | Hospices Civils de Lyon | 200 | 2014-08-01 | 2025-10-02 |
| Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions Imatinib Mesylate Tablets, 400 mg - Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor | Phase 2 / Phase 3 | Completed | Amneal Pharmaceuticals, LLC | 48 | 2014-02-01 | 2014-06-27 |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study Peginterferon α2b, Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | University of Jena | 717 | 2012-08-24 | 2023-05-10 |
| European Stop Tyrosine Kinase Inhibitor Study Stopping treatment with TKI - Chronic Myeloid Leukemia | Phase 3 | Completed | European LeukemiaNet | 868 | 2012-05-30 | 2021-11-05 |
| Nilotinib in PH+, BCR-, ABL+ CML Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 109 | 2012-01-01 | 2018-08-06 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 421 | 2011-04-01 | 2016-03-03 |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients Nilotinib, Imatinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 267 | 2011-04-01 | 2016-04-08 |
| Allogeneic Stem Cell Transplantation for Children With CML Fludarabine, Thiotepa, Melphalan - Chronic Myeloid Leukemia | Phase 2 / Phase 3 | Completed | St. Anna Kinderkrebsforschung | 13 | 2009-04-30 | 2021-04-15 |
| A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 6 | 2009-01-01 | 2017-02-28 |
| Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Bosutinib, imatinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Pfizer | 502 | 2008-02-05 | 2019-01-08 |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy StemEx® - Hematologic Malignancies, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Gamida Cell -Teva Joint Venture Ltd. | 101 | 2007-10-01 | 2015-07-10 |
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Alentuzumab, Globulina antilinfocitaria - Acute Myeloblastic Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Completed | Gruppo Italiano Trapianto di Midollo Osseo | 121 | 2005-03-01 | 2023-03-10 |
| Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) STI571 (400 mg/day; or 800 mg/day) - Chronic Myeloid Leukemia | Phase 3 | Completed | University of Bologna | 2004-06-01 | 2007-08-10 | |
| STI571 ProspectIve RandomIzed Trial: SPIRIT Imatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon - Chronic Myeloid Leukemia | Phase 3 | Completed | Poitiers University Hospital | 789 | 2003-09-01 | 2020-04-13 |
| Stem Cell Transplantation for Patients With Hematologic Malignancies Allogeneic Stem Cell Transplantation, Chemotherapy and antibodies - Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia | Phase 3 | Completed | St. Jude Children's Research Hospital | 33 | 2002-05-01 | 2009-01-29 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Refractory, with Excess of Blasts (2) · Myelodysplastic Syndromes (2) · Primary Myelofibrosis (2) · Gastrointestinal Stromal Tumors (1) · Hematologic Neoplasms (1) · Hemoglobinuria, Paroxysmal (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myelomonocytic, Juvenile (1) · Lymphoma (1)
Bone Marrow Diseases (16) · Chronic Disease (16) · Disease Attributes (16) · Hematologic Diseases (16) · Hemic and Lymphatic Diseases (16) · Leukemia (16) · Leukemia, Myeloid (16) · Neoplasms (16) · Neoplasms by Histologic Type (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Myeloproliferative Disorders (15) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4)
nilotinib (6) · Imatinib Mesylate (5) · Mycophenolic Acid (2) · fludarabine (2) · Antibodies (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cytarabine (1) · Drug Therapy (1) · Granulocyte Colony-Stimulating Factor (1) · Melphalan (1) · Tacrolimus (1) · Thiotepa (1) · Whole-Body Irradiation (1) · bosutinib (1)
Novartis Pharmaceuticals (3) · Amneal Pharmaceuticals, LLC (1) · Dartmouth-Hitchcock Medical Center (1) · European LeukemiaNet (1) · Gamida Cell -Teva Joint Venture Ltd. (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Hospices Civils de Lyon (1) · Pfizer (1) · Poitiers University Hospital (1) · St. Anna Kinderkrebsforschung (1) · St. Jude Children's Research Hospital (1) · University of Bologna (1) · University of Jena (1)
Italy (6) · France (4) · United States (4) · Czechia (3) · Germany (3) · India (3) · Argentina (2) · Brazil (2) · Canada (2) · China (2) · Colombia (2) · Hungary (2) · Israel (2) · Mexico (2) · Russia (2)
Agha Mounzer, MD (1) · Alberto Bosi, MD (1) · Alessandro Rambaldi, MD (1) · Andreas Hochhaus, Prof. MD (1) · Ashutosh Jani, MD (1) · Celia Grosskreutz, MD (1) · Christelle Ferra, MD (1) · Cristina Arbona, MD (1) · Dr. Cristina Diaz de Heredia, MD (1) · Dr. Mi Kwon, MD (1) · Dr. Pere Barba, MD (1) · Entezam Sahovic, MD (1)
PMID 19264678, PMID 19797518, PMID 21175313, PMID 21447834, PMID 21450900, PMID 22692507, PMID 22825216, PMID 22949154, PMID 23116602, PMID 24105694, PMID 24123600, PMID 24919837, PMID 24944159, PMID 25361995, PMID 25766724, PMID 26474455, PMID 27470600, PMID 27890936, PMID 28572163, PMID 28699641, PMID 29477778, PMID 29510895, PMID 29735299, PMID 35235189, PMID 37553873, PMID 42069411